Multi-provincial Cohort for Hypertension (MUCH)

Hypertension Clinical Trial

Official title:

Multi-provincial Cohort for Hypertension in China

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03150888
• Other study ID #: 2016YFC0900902
• Status: Recruiting
• Start date: July 3, 2017
• Est. completion date: December 2020

Study information

• Verified date: January 2020
• Source: Beijing Institute of Heart, Lung and Blood Vessel Diseases
• Contact: Yue Qi, PhD
• Phone: +861064456324
• Email: qiyue_bjcn[@]163.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The purpose of this study is to construct hypertension specialized cohort using uniform standards and specifications. This study timely collected multi-dimensional clinical information through electronic medical records, mobile health, data integration, informatics and computer modern techniques, linking self-reported data and big data platforms from different sources to timely obtain the incidence and mortality data, and integrating hypertension cohort samples and the associated clinical records systematically, in order to build a 30-thousand hypertension specialized cohort with fine phenotypic data and blood/urine samples, thus far to provide support for the development of precise medicine research and related industries.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30000
• Est. completion date: December 2020
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Clinical diagnosis of hypertension

• over 18 years old

• ti sign the informed consent

Exclusion Criteria:

• with life-threatening severe disease, such as severe tumor or AIDs

• pregnancy or lactating women,or plan to pregnant within half a year,

• with severe mental disorders

• participating in clinical trials

Related Conditions & MeSH terms

• Hypertension

Intervention

Drug:
• Antihypertensive Agents
Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.

Other:
• Cardiovascular risk factors
Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.

Locations

Country	Name	City	State
China	Beijing Anzhen Hospital	Beijing
China	Beijing Tiantan Hospital	Beijing
China	Beijing Tsinghua Chang Gung Hospital	Beijing
China	Southwest Hospital, China	Chongqing
China	Nanfang Hospital of Southern Medical University	Guangzhou
China	Ruijin Hospital	Shanghai

Sponsors (6)

Lead Sponsor	Collaborator
Beijing Institute of Heart, Lung and Blood Vessel Diseases	Beijing Tiantan Hospital, Beijing Tsinghua Chang Gung Hospital, Nanfang Hospital of Southern Medical University, Ruijin Hospital, Southwest Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite end point of major cardiovascular and cerebrovascular events	Composite end point of major cardiovascular and cerebrovascular events	From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
Secondary	New-onset of cardiovascular events	New-onset of cardiovascular events	From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
Secondary	New-onset of stroke	New-onset of stroke	From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
Secondary	Total death	Total death	From date of enrollment until date of death from all cause, assessed up to 3 year
Secondary	Major bleeding	Major bleeding	From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
Secondary	Atrial fibrillation	Atrial fibrillation	From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year